co.don AG to grow cartilage cell transplants for Asklepios Group
(Thomson Reuters ONE) -
co.don AG /
co.don AG to grow cartilage cell transplants for Asklepios Group
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* Framework agreement signed with Germany's largest private clinic group
The biotech company co.don AG is to provide the Asklepios Group with cartilage
cell transplants from its laboratories in Teltow from July 2011. The company's
German distribution partner, ORMED GmbH, was able to sign a corresponding
framework agreement. This will enable patients at the Asklepios Clinics
throughout Germany to be treated with the cell-based biological drug ARTROCELL
3D(® )/ co.don chondrosphere(®). The product is to be used for the regenerative
treatment of damaged cartilage, in knee joints for instance.
"The Asklepios Clinics are a strong partner for the deployment of our products
for the treatment of damaged articular cartilage", says Dr. Andreas Baltrusch,
CEO of co.don AG. "The clinics are the market leader in the private hospital
sector and are well-known for having the highest quality standards and
practising cutting-edge, patient-oriented medicine. The cell-biological products
from co.don AG are an ideal addition to the services offered by the Askepios
Clinics", Baltrusch added.
The product ARTROCELL 3D(®) / co.don chondrosphere(®) is manufactured 100 per
cent autologously, i.e. from the patient's own cells using their own serum. No
genetic manipulation is applied to breed or grow these cells and no external
substances such as antibiotics or antifungal agents are used.
These cartilage cell transplants are used in orthopaedic surgery to treat
articular cartilage defects. The transplants from the laboratories of co.don AG
are inserted orthopaedically into each defective area. This ensures that the
operation is as comfortable for the patient as possible. The use of regenerative
cartilage surgery at an early stage can obviate the need for a subsequent
prosthesis. As they are made exclusively from the body's own substances, the
cartilage cell transplants used for the treatment are not expected to cause any
rejection. The success rate for this regenerative treatment method is over 90
per cent.
About co.don AG:
The company is based in Teltow, Brandenburg, and was founded in 1993. Since
2001 the bio-pharmaceutical specialist has been listed on the Frankfurt Stock
Exchange (ISIN: DE0005173603). co.don AG uses tissue engineering - the
cultivation and growth of autologous tissue cells - to develop innovative
products and therapeutic concepts for the orthopaedic and neurosurgical markets.
The cell-based biological drugs (autologous cell transplants for articular
cartilage and intervertebral disks) are produced without the use of antibiotics,
growth factors and genetic engineering. The Management Board of co.don® AG is
made up of Dr Andreas Baltrusch (CEO) and Ms Vilma Siodla (COO).
Further information is available from: www.codon.de
Press contact
BrunoMedia Communication GmbH
Gerd J. Gauger
Bonner Straße 328
50968 Köln
Tel: +49 (0)221 348 038 10
Fax: +49 (0)221 348 038 41
Email:codon(at)brunomedia.de
--- End of Message ---
co.don AG
Warthestr. 21 Teltow Germany
WKN: 517360 ;ISIN: DE0005173603;Index:CDAX;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Niedersächsische Börse zu Hannover,
General Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Press release (PDF):
http://hugin.info/132731/R/1537835/469632.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: co.don AG via Thomson Reuters ONE
[HUG#1537835]
Unternehmensinformation / Kurzprofil:
Datum: 11.08.2011 - 09:04 Uhr
Sprache: Deutsch
News-ID 57159
Anzahl Zeichen: 4772
contact information:
Town:
Teltow
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 197 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"co.don AG to grow cartilage cell transplants for Asklepios Group"
steht unter der journalistisch-redaktionellen Verantwortung von
co.don AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
